Labour minister sidelined over puberty blocker trial concerns

By the Editorial Team · Monday, July 6, 2026

The UK government has banned puberty blockers on the NHS but is conducting a clinical trial involving 226 children to gather more definitive evidence on their safety and efficacy. This trial has sparked controversy and internal government conflict, with concerns raised about the ethics and safeguarding of participating minors.

In late 2024, the UK government imposed a permanent ban on puberty blockers within the National Health Service (NHS), following a report by Dr. Hilary Cass, a paediatrician who highlighted the lack of evidence regarding the safety and efficacy of these drugs and cross-sex hormones in children. Despite the ban, the government has recently moved forward with a clinical trial involving several hundred children to assess whether more conclusive evidence can be gathered to support or refute the ban.

The trial, known as the Pathways study, aims to evaluate the effects of puberty blockers on around 226 participants. However, the decision to continue with the trial has led to internal government tensions. Preet Kaur Gill, who was appointed minister for health innovation and safety in May 2026, reportedly expressed concerns about the safety and ethics of the trial. Gill, a former social worker, had previously warned that credible safeguarding issues related to puberty blockers were not being adequately addressed.

According to sources within Whitehall, Gill has been sidelined from involvement in the Pathways trial. While government officials contend that changes in ministerial responsibilities are routine and that ministers are expected to adhere to established policy positions, insiders suggest her exclusion is linked to her scepticism about the trial’s continuation. Some critics argue that having a minister with safety concerns actively engaged in overseeing the trial could better represent broader public unease over what they describe as an alarming experiment on children.

The government maintains that the trial is necessary to collect robust data that could clarify the long-term impact of puberty blockers and inform future NHS guidelines. Supporters contend that without such evidence, the medical community cannot adequately address the needs of transgender youth. Opponents, including various advocacy groups and some healthcare professionals, view the trial as controversial, citing potential risks and ethical objections.

The Pathways study remains a focal point in the ongoing debate over medical treatments for gender dysphoria in minors. The government’s approach illustrates the challenge of balancing evidence-based policy-making, public safety concerns, and the rights of young people seeking gender-affirming care.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.